Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Report Format: PDF+Excel | Report ID: SR112023A6549
Year End
sale
Buy Now
Market Overview:
The global antisense & RNAi therapeutics market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.
Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. It is also used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. It is employed for treating various respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. RNAi therapy also assists in preventing the production of specific genes that cause diseases or contribute to the growth of diseases.
.webp)
Antisense & RNAi Therapeutics Market Trends:
The growing demand for antisense and RNAi therapeutics to treat uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, represents one of the key factors driving the market. Besides this, there is a rise in the demand for disease management to regulate gene expression by malfunctioning genes across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, key market players are extensively investing in research and development (R&D) activities to develop molecules based on antisense technology. They are also collaborating with contract research organizations (CROs) working on drug delivery, which is strengthening the growth of the market. In addition, the growing demand for antisense RNA to prevent disease onset and reduce disease progression is positively influencing the market. Apart from this, the rising need for curing and preventing diseases, such as cancer, human immunodeficiency virus (HIV), and other diseases caused by mutating viruses is bolstering the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antisense & RNAi therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, route of administration and application.
Breakup by Technology:
- RNA Interference
- siRNA
- miRNA
- Antisense RNA
Breakup by Route of Administration:
- Intravenous Route
- Subcutaneous Route
- Intrathecal Route
- Pulmonary Delivery
- Intraperitoneal Injection
- Others
Breakup by Application:
- Oncology
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Renal Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2022 |
| Historical Period | 2017-2022 |
| Forecast Period | 2023-2028 |
| Units | US$ Billion |
| Segment Coverage | Technology, Route of Administration, Application, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered | Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global antisense & RNAi therapeutics market was valued at US$ 1.5 Billion in 2022.
We expect the global antisense & RNAi therapeutics market to exhibit a CAGR of 8.3% during 2023-2028.
The growing need for treating and preventing chronic diseases that are caused by a mutating virus is primarily driving the global antisense & RNAi therapeutics market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment procedures for respiratory diseases to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals, thereby negatively impacting the global market for antisense & RNAi therapeutics.
Based on the technology, the global antisense & RNAi therapeutics market has been segregated into RNA interference and antisense RNA. Currently, antisense RNA holds the largest market share.
Based on the route of administration, the global antisense & RNAi therapeutics market can be bifurcated into intravenous route, subcutaneous route, intrathecal route, pulmonary delivery, intraperitoneal injection, and others. Among these, pulmonary delivery exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global antisense & RNAi therapeutics market include Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics, and Sirnaomics Inc.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More